A comparison of microbiology and demographics among patients with healthcare-associated, hospital-acquired, and ventilator-associated pneumonia: a retrospective analysis of 1184 patients from a large, international study

Andrew A Quartin, Ernesto G Scerpella, Sailaja Puttagunta, Daniel H Kett, Andrew A Quartin, Ernesto G Scerpella, Sailaja Puttagunta, Daniel H Kett

Abstract

Background: Acceptance of healthcare-associated pneumonia (HCAP) as an entity and the associated risk of infection by potentially multidrug-resistant (MDR) organisms such as methicillin-resistant Staphylococcus aureus (MRSA), Pseudomonas and Acinetobacter have been debated. We therefore compared patients with HCAP, hospital-acquired pneumonia (HAP), and ventilator-associated pneumonia (VAP) enrolled in a trial comparing linezolid with vancomycin for treatment of pneumonia.

Methods: The analysis included all patients who received study drug. HCAP was defined as pneumonia occurring < 48 hours into hospitalization and acquired in a long-term care, subacute, or intermediate health care facility; following recent hospitalization; or after chronic dialysis.

Results: Data from 1184 patients (HCAP = 199, HAP = 379, VAP = 606) were analyzed. Compared with HAP and VAP patients, those with HCAP were older, had slightly higher severity scores, and were more likely to have comorbidities. Pseudomonas aeruginosa was the most common gram-negative organism isolated in all pneumonia classes [HCAP, 22/199 (11.1%); HAP, 28/379 (7.4%); VAP, 57/606 (9.4%); p = 0.311]. Acinetobacter spp. were also found with similar frequencies across pneumonia groups. To address potential enrollment bias toward patients with MRSA pneumonia, we grouped patients by presence or absence of MRSA and found little difference in frequencies of Pseudomonas and Acinetobacter.

Conclusions: In this population of pneumonia patients, the frequencies of MDR gram-negative pathogens were similar among patients with HCAP, HAP, or VAP. Our data support inclusion of HCAP within nosocomial pneumonia guidelines and the recommendation that empiric antibiotic regimens for HCAP should be similar to those for HAP and VAP.

Trial registration: ClinicalTrials.gov NCT00084266.

References

    1. American Thoracic Society. Infectious Diseases Society of America: guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005;171(4):388–416.
    1. Kollef MH, Shorr A, Tabak YP, Gupta V, Liu LZ, Johannes RS. Epidemiology and outcomes of health-care-associated pneumonia: results from a large US database of culture-positive pneumonia.[Erratum appears in Chest. 2006 Mar;129(3):831] Chest. 2005;128(6):3854–3862. doi: 10.1378/chest.128.6.3854.
    1. Micek ST, Kollef KE, Reichley RM, Roubinian N, Kollef MH. Health care-associated pneumonia and community-acquired pneumonia: a single-center experience. Antimicrob Agents Chemother. 2007;51(10):3568–3573. doi: 10.1128/AAC.00851-07.
    1. Shorr AF, Zilberberg MD, Micek ST, Kollef MH. Prediction of infection due to antibiotic-resistant bacteria by select risk factors for health care-associated pneumonia. Arch Intern Med. 2008;168(20):2205–2210. doi: 10.1001/archinte.168.20.2205.
    1. Zilberberg MD, Shorr AF, Micek ST, Mody SH, Kollef MH. Antimicrobial therapy escalation and hospital mortality among patients with health-care-associated pneumonia: a single-center experience. Chest. 2008;134(5):963–968. doi: 10.1378/chest.08-0842.
    1. Madaras-Kelly KJ, Remington RE, Fan VS, Sloan KL. Predicting antibiotic resistance to community-acquired pneumonia antibiotics in culture-positive patients with healthcare-associated pneumonia. J Hosp Med. 2012;7(3):195–202. doi: 10.1002/jhm.942.
    1. Attridge RT, Frei CR, Restrepo MI, Lawson KA, Ryan L, Pugh MJV, Anzueto A, Mortensen EM. Guideline-concordant therapy and outcomes in healthcare-associated pneumonia. Eur Respir J. 2011;38(4):878–887. doi: 10.1183/09031936.00141110.
    1. Webb BJ, Dangerfield BS, Pasha JS, Agrwal N, Vikram HR. Guideline-concordant antibiotic therapy and clinical outcomes in healthcare-associated pneumonia. Respir Med. 2012;106(11):1606–1612. doi: 10.1016/j.rmed.2012.08.003.
    1. Jung JY, Park MS, Kim YS, Park BH, Kim SK, Chang J, Kang YA. Healthcare-associated pneumonia among hospitalized patients in a Korean tertiary hospital. BMC Infect Dis. 2011;11:61. doi: 10.1186/1471-2334-11-61.
    1. Seki M, Hashiguchi K, Tanaka A, Kosai K, Kakugawa T, Awaya Y, Kurihara S, Izumikawa K, Kakeya H, Yamamoto Y. et al.Characteristics and disease severity of healthcare-associated pneumonia among patients in a hospital in Kitakyushu, Japan. J Infect Chemother. 2011;17(3):363–369. doi: 10.1007/s10156-010-0127-8.
    1. Sugisaki M, Enomoto T, Shibuya Y, Matsumoto A, Saitoh H, Shingu A, Narato R, Nomura K. Clinical characteristics of healthcare-associated pneumonia in a public hospital in a metropolitan area of Japan. J Infect Chemother: official journal of the Japan Society of Chemotherapy. 2012;18(3):352–360. doi: 10.1007/s10156-011-0344-9.
    1. Giannella M, Pinilla B, Capdevila JA, Martinez Alarcon J, Munoz P, Lopez Alvarez J, Bouza E. Pneumonia treated in the internal medicine department: focus on healthcare-associated pneumonia. Clin Microbiol Infec: the official publication of the European Society of Clinical Microbiology and Infectious Diseases. 2012;18(8):786–794. doi: 10.1111/j.1469-0691.2011.03757.x.
    1. Shindo Y, Ito R, Kobayashi D, Ando M, Ichikawa M, Shiraki A, Goto Y, Fukui Y, Iwaki M, Okumura J. et al.Risk factors for drug-resistant pathogens in community-acquired and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2013;188(8):985–995. doi: 10.1164/rccm.201301-0079OC.
    1. Ma HM, Ip M, Woo J, Hui DS, Lui GC, Lee NL, Chan PK, Rainer TH. Risk factors for drug-resistant bacterial pneumonia in older patients hospitalized with pneumonia in a Chinese population. QJM. 2013;106(9):823–829. doi: 10.1093/qjmed/hct152.
    1. Falcone M, Corrao S, Licata G, Serra P, Venditti M. Clinical impact of broad-spectrum empirical antibiotic therapy in patients with healthcare-associated pneumonia: a multicenter interventional study. Intern Emerg Med. 2012;7(6):523–531. doi: 10.1007/s11739-012-0795-8.
    1. Carrabba M, Zarantonello M, Bonara P, Hu C, Minonzio F, Cortinovis I, Milani S, Fabio G. Severity assessment of healthcare-associated pneumonia and pneumonia in immunosuppression. Eur Respir J. 2012;40(5):1201–1210. doi: 10.1183/09031936.00187811.
    1. Jeong BH, Koh WJ, Yoo H, Um SW, Suh GY, Chung MP, Kim H, Kwon OJ, Jeon K. Performances of prognostic scoring systems in patients with healthcare-associated pneumonia. Clin Infect Dis. 2013;56(5):625–632. doi: 10.1093/cid/cis970.
    1. Carratala J, Mykietiuk A, Fernandez-Sabe N, Suarez C, Dorca J, Verdaguer R, Manresa F, Gudiol F. Health care-associated pneumonia requiring hospital admission: epidemiology, antibiotic therapy, and clinical outcomes. Arch Intern Med. 2007;167(13):1393–1399. doi: 10.1001/archinte.167.13.1393.
    1. Chalmers JD, Taylor JK, Singanayagam A, Fleming GB, Akram AR, Mandal P, Choudhury G, Hill AT. Epidemiology, antibiotic therapy, and clinical outcomes in health care-associated pneumonia: a UK cohort study. Clin Infect Dis. 2011;53(2):107–113. doi: 10.1093/cid/cir274.
    1. Grenier C, Pepin J, Nault V, Howson J, Fournier X, Poirier M-S, Cabana J, Craig C, Beaudoin M, Valiquette L. Impact of guideline-consistent therapy on outcome of patients with healthcare-associated and community-acquired pneumonia. J Antimicrob Chemother. 2011;66(7):1617–1624. doi: 10.1093/jac/dkr176.
    1. Garcia-Vidal C, Viasus D, Roset A, Adamuz J, Verdaguer R, Dorca J, Gudiol F, Carratala J. Low incidence of multidrug-resistant organisms in patients with healthcare-associated pneumonia requiring hospitalization. Clin Microbiol Infec. 2011;17(11):1659–1665. doi: 10.1111/j.1469-0691.2011.03484.x.
    1. Ewig S, Welte T, Chastre J, Torres A. Rethinking the concepts of community-acquired and health-care-associated pneumonia. Lancet Infect Dis. 2010;10(4):279–287. doi: 10.1016/S1473-3099(10)70032-3.
    1. Lopez A, Amaro R, Polverino E. Does health care associated pneumonia really exist? Eur J Intern Med. 2012;23(5):407–411. doi: 10.1016/j.ejim.2012.05.006.
    1. Wunderink RG, Niederman MS, Kollef MH, Shorr AF, Kunkel MJ, Baruch A, McGee WT, Reisman A, Chastre J. Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study. Clin Infect Dis. 2012;54(5):621–629. doi: 10.1093/cid/cir895.
    1. Agbaht K, Diaz E, Munoz E, Lisboa T, Gomez F, Depuydt PO, Blot SI, Rello J. Bacteremia in patients with ventilator-associated pneumonia is associated with increased mortality: A study comparing bacteremic vs. nonbacteremic ventilator-associated pneumonia. Crit Care Med. 2007;35(9):2064–2070. doi: 10.1097/01.CCM.0000277042.31524.66.
    1. Montravers P, Veber B, Auboyer C, Dupont H, Gauzit R, Korinek AM, Malledant Y, Martin C, Moine P, Pourriat JL. Diagnostic and therapeutic management of nosocomial pneumonia in surgical patients: results of the Eole study. Crit Care Med. 2002;30(2):368–375. doi: 10.1097/00003246-200202000-00017.
    1. Richards MJ, Edwards JR, Culver DH, Gaynes RP. Nosocomial infections in medical intensive care units in the United States. National Nosocomial Infections Surveillance System. Crit Care Med. 1999;27(5):887–892. doi: 10.1097/00003246-199905000-00020.
    1. Chastre J, Fagon J-Y. Ventilator-associated pneumonia. Am J Respir Crit Care Med. 2002;165(7):867–903. doi: 10.1164/ajrccm.165.7.2105078.
    1. Song J-H. Asian Hospital Acquired Pneumonia Working G. Treatment recommendations of hospital-acquired pneumonia in Asian countries: first consensus report by the Asian HAP Working Group. Am J Infect Control. 2008;36(4 Suppl):S83–S92.
    1. Torres A, Ewig S, Lode H, Carlet J. European HAPwg. Defining, treating and preventing hospital acquired pneumonia: European perspective. Intensive Care Med. 2009;35(1):9–29. doi: 10.1007/s00134-008-1336-9.
    1. Kett DH, Cano E, Quartin AA, Mangino JE, Zervos MJ, Peyrani P, Cely CM, Ford KD, Scerpella EG, Ramirez JA. et al.Implementation of guidelines for management of possible multidrug-resistant pneumonia in intensive care: an observational, multicentre cohort study. Lancet Infect Dis. 2011;11(3):181–189. doi: 10.1016/S1473-3099(10)70314-5.
    1. Koulenti D, Lisboa T, Brun-Buisson C, Krueger W, Macor A, Sole-Violan J, Diaz E, Topeli A, DeWaele J, Carneiro A. et al.Spectrum of practice in the diagnosis of nosocomial pneumonia in patients requiring mechanical ventilation in European intensive care units. Crit Care Med. 2009;37(8):2360–2368. doi: 10.1097/CCM.0b013e3181a037ac.
    1. Venditti M, Falcone M, Corrao S, Licata G, Serra P. Study Group of the Italian Society of Internal M. Outcomes of patients hospitalized with community-acquired, health care-associated, and hospital-acquired pneumonia.[Summary for patients in Ann Intern Med. 2009 Jan 6;150(1):I36; PMID: 19124813] Ann Intern Med. 2009;150(1):19–26. doi: 10.7326/0003-4819-150-1-200901060-00005.
    1. Kirtland SH, Corley DE, Winterbauer RH, Springmeyer SC, Casey KR, Hampson NB, Dreis DF. The diagnosis of ventilator-associated pneumonia: a comparison of histologic, microbiologic, and clinical criteria. Chest. 1997;112(2):445–457. doi: 10.1378/chest.112.2.445.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner